Since SLC7A11 encodes a subunit of the cystine/glutamate transporter XCT that supplies cells with cysteine, a key source of GSH, ARID1A-deficient cancer cells are specifically vulnerable to inhibitors of the GSH metabolic pathway, such as APR-246 for GSH and buthionine sulfoximine for glutamate-cysteine ligase catalytic subunit (GCLC), an essential subunit for ATP-dependent enzyme glutamate-cysteine ligase synthetase (GCL) that catalyzes the rate-limiting step of glutamate ligation with cysteine during GSH synthesis [50]. This evidence concerns the gene ARID1A and cancer.